BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...Investors and General Atlantic. Fellow new investor Cormorant Asset Management and existing investors Foresite Capital, Bain Capital Life Sciences...
BioCentury | Oct 23, 2020
Finance

Sarepta joins investor trio in Aavanti’s $107M series A round to develop gene therapy for Friedreich’s ataxia

...But with preclinical data from three species now in place, a group comprising Perceptive Advisors, Bain Capital Life Sciences...
BioCentury | Oct 23, 2020
Deals

Roche in $350M deal with Sommadossi’s Atea for what it believes could be first oral COVID-19 antiviral

...million in a series D round in May to fund its development for the indication. Bain Capital Life Sciences...
BioCentury | Oct 9, 2020
Finance

Kronos’ post-IPO gains build on $1B+ postmoney valuation

...$215 million in a series D round led by Bain Capital Life Sciences...
BioCentury | Aug 27, 2020
Product Development

Freenome maps path forward for blood-based cancer screenings with $270M C round

...cancer screening technology beyond colorectal cancer.New investor Bain Capital Life Sciences...
BioCentury | Jul 3, 2020
Finance

On heels of $100M raise, Annexon joins burgeoning IPO queue

...Management, Janus Henderson Investors and Logos Capital. Also participating were existing investors Adage Capital Partners, Bain Capital Life Sciences...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...Marc Cohen -- and first-time backer Perceptive. Also investing were Adage Capital Management, Axil Capital, Bain Capital Life Sciences...
BioCentury | May 28, 2020
Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

...bringing the total raised in the round so far to about $50 million. Existing investors Bain Capital Life Sciences...
BioCentury | May 21, 2020
Finance

With repurposed antiviral, Atea draws $215M as it preps Phase II COVID-19 trial

...a clinical study of the pill, with dosing of coronavirus patients to begin this month. Bain Capital Life Sciences...
BioCentury | May 20, 2020
Finance

Quality control company Rapid Micro raises $120M in equity and debt

...led by Ally Bridge Group, with contributions from new investor Endeavour Vision and prior investors Bain Capital Life Sciences...
Items per page:
1 - 10 of 44
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

...Investors and General Atlantic. Fellow new investor Cormorant Asset Management and existing investors Foresite Capital, Bain Capital Life Sciences...
BioCentury | Oct 23, 2020
Finance

Sarepta joins investor trio in Aavanti’s $107M series A round to develop gene therapy for Friedreich’s ataxia

...But with preclinical data from three species now in place, a group comprising Perceptive Advisors, Bain Capital Life Sciences...
BioCentury | Oct 23, 2020
Deals

Roche in $350M deal with Sommadossi’s Atea for what it believes could be first oral COVID-19 antiviral

...million in a series D round in May to fund its development for the indication. Bain Capital Life Sciences...
BioCentury | Oct 9, 2020
Finance

Kronos’ post-IPO gains build on $1B+ postmoney valuation

...$215 million in a series D round led by Bain Capital Life Sciences...
BioCentury | Aug 27, 2020
Product Development

Freenome maps path forward for blood-based cancer screenings with $270M C round

...cancer screening technology beyond colorectal cancer.New investor Bain Capital Life Sciences...
BioCentury | Jul 3, 2020
Finance

On heels of $100M raise, Annexon joins burgeoning IPO queue

...Management, Janus Henderson Investors and Logos Capital. Also participating were existing investors Adage Capital Partners, Bain Capital Life Sciences...
BioCentury | Jun 17, 2020
Finance

Crossovers pile into new rounds for C4, 4D Molecular

...Marc Cohen -- and first-time backer Perceptive. Also investing were Adage Capital Management, Axil Capital, Bain Capital Life Sciences...
BioCentury | May 28, 2020
Finance

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

...bringing the total raised in the round so far to about $50 million. Existing investors Bain Capital Life Sciences...
BioCentury | May 21, 2020
Finance

With repurposed antiviral, Atea draws $215M as it preps Phase II COVID-19 trial

...a clinical study of the pill, with dosing of coronavirus patients to begin this month. Bain Capital Life Sciences...
BioCentury | May 20, 2020
Finance

Quality control company Rapid Micro raises $120M in equity and debt

...led by Ally Bridge Group, with contributions from new investor Endeavour Vision and prior investors Bain Capital Life Sciences...
Items per page:
1 - 10 of 44